retatrutide ema approval 💉 A triple-action once-weekly injection can significantly lower blood sugar and body weight in people with type 2 diabetes, a new phase 3 trial shows. is part of an emerging generation Retatrutide (LY-3437943) Market Analysis, 2033:

Rowlands A, Davies M, Dempsey P, Edwardson C, Razieh C, Yates T (2021) Wrist-worn accelerometers: recommending ~1.0 mg as the minimum clinically important difference (MCID) in daily average acceleration for inactive adults

And its neuroprotective effect has become a research hotspot in recent years

For an athlete whose performance depends on power, explosiveness, and strength, thats a real cost that may offset the body composition benefit entirely. This occurs, he said, because people on GLP-1s dont selectively burn fat

Lawitz, E

How GLP-1 Drugs Influence Nutritional Status Important Clarification It is essential not to conflate GLP-1 therapy with bariatric surgery